Antiviral Drugs - Eastern Africa

Eastern Africa

The Eastern Africa region is expected to witness significant growth in the Antiviral Drugs market.
Revenue in this market is projected to reach US$71.69m in 2024.
With an annual growth rate (CAGR 2024-2029) of 2.25%, the market volume is expected to reach US$80.11m by 2029.
In comparison to other countries worldwide, United States is anticipated to generate the highest revenue in the Antiviral Drugs market, with an estimated amount of US$30,640.00m in 2024.
Eastern Africa is experiencing a surge in demand for antiviral drugs due to the increasing prevalence of viral diseases in the region.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Antiviral Drugs in Eastern Africa has been on the rise in recent years.

Customer preferences: There has been an increasing demand for Antiviral Drugs in Eastern Africa due to the high prevalence of viral diseases such as HIV/AIDS, hepatitis B and C, and influenza. The majority of the population affected by these diseases are in low-income areas, which has led to an increase in demand for affordable antiviral drugs.

Trends in the market: The Antiviral Drugs market in Eastern Africa has witnessed a shift from branded drugs to generic drugs due to the affordability and accessibility of generic drugs. The market has also seen an increase in the number of local manufacturers producing antiviral drugs, which has led to increased competition and reduced prices.

Local special circumstances: The high prevalence of viral diseases in Eastern Africa has led to an increase in demand for antiviral drugs, which has created an opportunity for local manufacturers to produce affordable generic drugs. However, the low purchasing power of the population has resulted in a high demand for low-priced drugs, which has led to a price war among manufacturers.

Underlying macroeconomic factors: The economic growth in Eastern Africa has been slow, which has resulted in low purchasing power and limited access to healthcare services. The high prevalence of viral diseases has also put a strain on the healthcare system, which has resulted in limited access to antiviral drugs. The government has implemented policies to increase access to healthcare services, which has led to an increase in demand for antiviral drugs. However, the limited resources and infrastructure have made it challenging to meet the demand for antiviral drugs in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.